Skip to main content
dana-farber.org

Advances in Cancer Medicine: Our Momentum of Discovery

 

Featured Content |Content Library

2026 American Society of Clinical Oncology (ASCO) Annual Meeting Symposium

2026 American Society of Clinical Oncology (ASCO) Annual Meeting

AI Tool Could Speed Discovery of New Cancer Drug Targets News

AI Tool Could Speed Discovery of New Cancer Drug Targets

Immune Activity Shift a Key Early Step in Breast Cancer Formation News

Immune Activity Shift a Key Early Step in Breast Cancer Formation

Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer News

Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer

CME: Early Detection and Interception of Cancer Course

CME: Early Detection and Interception of Cancer

Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies News

Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies

Education/CME

Receive Dana-Farber's
e-newsletter, Momentum,
to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.